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Background: Sitagliptin is a novel antidiabetic agent with a low risk for hypoglycemia. We investigated the efficacy and safety 
of sitagliptin when patients switched from a sulfonylurea to sitagliptin and identified good candidates for the switch. 
Methods: Sixty-one patients with type 2 diabetes switched from glimepiride with metformin to sitagliptin with metformin due to 
clinical hypoglycemia. Serum glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and 2-hour postprandial plasma glu-
cose (2h-PPG) before and 12 and 24 weeks after the drug switch were checked.
Results: HbA1c and FPG levels did not change 12 or 24 weeks after the switch; however, the 2h-PPG level decreased from 
218.0±67.5 mg/dL at baseline to 197.1±69.9 mg/dL at 12 weeks and 192.3±67.4 mg/dL at 24 weeks after switching drugs 
(P=0.045, P=0.018, respectively). All but one patient no longer experienced hypoglycemia after discontinuing glimepiride. In a 
multivariate logistic regression analysis, a high homeostasis model assessment of insulin resistance and low baseline HbA1c level 
were independent predictors of an HbA1c ≤7% after switching to sitagliptin.
Conclusion: Glycemic control was not aggravated in patients 24 weeks after the drug switch, and symptomatic hypoglycemia 
decreased significantly. Patients with dominant insulin resistance may be good candidates for switching from a sulfonylurea to si-
tagliptin to reduce hypoglycemia. 
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INTRODUCTION
Sulfonylureas are the most widely used antidiabetic agents 
worldwide; however, concern has been raised about their possi-
ble adverse effects. These agents may cause weight gain, hypo-
glycemia, and β-cell exhaustion, resulting in limited effective-
ness (secondary failure) long-term [1-3]. Therefore, there is in-
terest in hyperglycemic agents with comparable glucose lower-
ing efficacy to sulfonylureas, but with less effect on hypoglyce-
mia and weight gain, which would improve the management of 
patients with type 2 diabetes mellitus.
 Dipeptidyl peptidase-4 (DPP-4) inhibitors have become a 
commonly used treatment for type 2 diabetes [4], and among 
these inhibitors, sitagliptin was the first approved agent. It acts 
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by preventing degradation of glucagon-like peptide-1 (GLP-1), 
thus potentiating the action of native GLP-1 by 2- to 3-fold. Si-
tagliptin causes glucose-dependent insulin secretion, decreases 
hepatic glucose output, and may have a trophic effect on pan-
creatic β-cells [5]. DPP-4 inhibitors are weight-neutral, and the 
incidences of hypoglycemia and adverse gastrointestinal ef-
fects in response to sitagliptin are similar to those with a place-
bo [6]. In addition, DPP-4 inhibitors increased the number of 
pancreatic β-cells and improved their function in a preclinical 
study [7].
 While both sulfonylureas and DPP-4 inhibitors increase in-
sulin release from pancreatic β-cells, their underlying mecha-
nisms differ. Thus, it might be possible to replace a sulfonyl-
urea with a DPP-4 inhibitor in certain patients with a high risk 
of hypoglycemia, but few relevant studies have been conduct-
ed. Thus, we investigated the efficacy and safety of sitagliptin 
when patients switched from a sulfonylurea to sitagliptin and 
identified good candidates for the drug switch to prevent symp-
tomatic hypoglycemia.
METHODS
Study design
This study was performed in patients with type 2 diabetes mel-
litus who visited the outpatient Division of the Endocrinology 
and Metabolism at Severance Hospital, Yonsei University Col-
lege of Medicine from October 2008 to December 2009. This 
protocol was approved by the Institutional Review Board of 
Yonsei University College of Medicine. Patients with symp-
tomatic hypoglycemia, defined as an event with subjective 
symptoms of hunger, anxiety, sweating, tremors, or palpita-
tions, were switched from glimepiride with metformin to sita-
gliptin with metformin without a change in the metformin 
dose. Patients who discontinued sitagliptin before 24 weeks or 
who changed the dose of their antidiabetic medication during 
the study period were excluded. The sitagliptin dose was 100 
mg once daily. All subjects were tested for serum glycated he-
moglobin (HbA1c), fasting plasma glucose (FPG), and  2-hour 
postprandial plasma glucose (2h-PPG) before and 12 and 24 
weeks after the drug switch.
 We divided the patients into two groups based on their status 
of glucose control at 12 or 24 weeks after the drug switch to 
identify good candidates for the switch (HbA1c ≤7% [ade-
quate control group, group 1] vs. HbA1c >7% [inadequate con-
trol group, group 2]). Factors affecting the efficacy of switching 
to sitagliptin were evaluated. The clinical parameters assessed 
in the two groups included age, sex, duration of diabetes, body 
mass index (BMI), plasma lipid concentration, pancreatic 
β-cell function, and degree of insulin resistance.
 The patients’ records were reviewed to verify the duration of 
diabetes and medication profiles. We calculated the BMI of the 
participants using the height and weight measurements from 
these records. FPG/2h-PPG levels were determined using a 
standard glucose oxidase method and a 747 automatic analyzer 
(Hitachi Instrument Service, Tokyo, Japan). Plasma triglycer-
ides, total cholesterol, and high density lipoprotein cholesterol 
were assayed using a routine Hitachi 7600 autoanalyzer (Hita-
chi Instrument Service). Low density lipoprotein cholesterol 
was calculated using the Friedewald equation. HbA1c level 
was measured by high-performance liquid chromatography us-
ing a Variant II Turbo system (Bio-Rad Laboratories, Hercules, 
CA, USA). The HbA1c assay was certified by the National 
Glycohemoglobin Standardization Program [8]. Serum insulin 
and C-peptide levels were measured in duplicate using an im-
munoradiometric assay method (Beckman Coulter, Fullerton, 
CA, USA). Insulin resistance was assessed using the homeo-
stasis model assessment of insulin resistance (HOMA-IR) 
equation as follows: HOMA-IR=[fasting insulin (μIU/mL)×
fasting serum glucose (mmol/L)/22.5]. HOMA-β was calculat-
ed to assess pancreatic β-cell function using the following for-
mula: 20×fasting insulin (μIU/mL)/fasting glucose (mmol/
L)−3.5 [9,10].
Statistical analysis
Continuous variables with a normal distribution have been ex-
pressed as means±SD and discrete variables as percentages. 
Statistical comparisons of HbA1c, FPG, and PPG levels at 12 
weeks and 24 weeks after switch were performed using paired 
t test. Intergroup differences in baseline characteristics were 
analyzed by Student t test for continuous variables or the chi-
square test for gender. Multivariate logistic regression analysis 
was used to examine the independent factors for predicting the 
efficacy when switching from a sulfonylurea to sitagliptin. All 
statistical analyses were performed using PASW statistics ver-
sion 18.0 (IBM Co., Armonk, NY, USA). A P<0.05 was con-
sidered significant.
RESULTS
Baseline characteristics
Sixty-one subjects (25 men and 36 women; mean age, 59.3±
11.6 years) were switched from glimepiride to sitagliptin due 
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to hypoglycemia and the treatment continued for at least 24 
weeks during the study period. Before the switch to sitagliptin, 
the mean HbA1c value was 7.5%±1.3%, FPG was 134.1±
36.0 mg/dL, and 2h-PPG was 218.0±67.5 mg/dL. The mean 
BMI was 24.7±3.1 kg/m2, and the mean diabetes duration was 
8.9±8.6 years. The mean dose of glimepiride before the switch 
was 2.6±1.7 mg/day, and the mean dose of metformin was 
995±476 mg/day (Table 1).
Efficacy and safety after the switch from a sulfonylurea to 
sitagliptin
The HbA1c level was 7.4%±1.4% at 12 weeks after the switch 
from glimepiride to sitagliptin and tended to decrease (7.3%±
1.2%) after 24 weeks (P=0.8, P=0.241, respectively). FPG 
was also comparable before and after switching drugs (134.1±
36.0 mg/dL at baseline, 137.2±37.8 mg/dL at 12 weeks after 
switching, 135.0±32.1 mg/dL at 24 weeks after switching). 
However, the switch from glimepiride to sitagliptin significant-
ly reduced the 2h-PPG level by 21 mg/dL (218.0±67.5 to 
197.1±69.9 mg/dL, P=0.045) at week 12 and by 26 mg/dL 
(218±67 to 192.3±67.4 mg/dL, P=0.018) at week 24 (Fig. 1). 
The proportion of patients who reached the target HbA1c level 
Table 1. Baseline Characteristcs of the Study Participants
Characteristic Value
Age, yr 59.3±11.6
Male    25 (40.9)
Duration of diabetes, yr 8.9±8.6
BMI, kg/m2 24.7±3.1
HbA1c, % 7.5±1.3
Fasting plasma glucose, mg/dL 134.1±36.0
Postprandial plasma glucose, mg/dL 218.0±67.5
Total cholesterol, mg/dL 174.7±37.6
Triglyceride, mg/dL 159.3±87.6
HDL-C, mg/dL 48.2±13.3
LDL-C, mg/dL 96.1±32.2
HOMA-IR 5.0±5.3
HOMA-β 44.8±30.8
Glimepiride dose, mg/day 2.6±1.7
Metformin dose, mg/day 995±476
Values are expressed as mean±SD or number (%).
BMI, body mass index; HbA1c, glycated hemoglobin; HDL-C, high 
density lipoprotein cholesterol; LDL-C, low density lipoprotein cho-
lesterol; HOMA-IR, homeostasis model assessment of insulin resis-
tance; HOMA-β, homeostasis model assessment of β-cell function.
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Fig. 1. (A) Changes in glycated hemoglobin 
(HbA1c), (B) fasting plasma glucose (FPG), 
(C) 2-hour postprandial glucose (2h-PPG) 
values in all patients, (D) HbA1c in group 1 
(HbA1c ≤7% at 12 weeks after switching), 
and (E) HbA1c in group 2 (HbA1c >7% at 
12 weeks after switching) before and after 
switching from glimepiride to sitagliptin. 
Data are presented as the mean±SD. Paired 
t test. aP<0.05 vs. baseline. 
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of <7% was 31.1% at baseline, which increased to 44.3% and 
42.6% at 12 and 24 weeks, respectively. All but one patient 
stopped experiencing hypoglycemia after discontinuing the 
sulfonylurea.
Predictive clinical characteristics of sitagliptin after the 
switch from the sulfonylurea
We divided the patients into two groups based on their status of 
glucose control at 12 weeks after switching drugs to evaluate 
the clinical factors affecting efficacy after the switch (HbA1c 
≤7% [adequate control group, group 1] vs. HbA1c >7% [in-
adequate control group, group 2]). In both groups, the HbA1c 
level did not increased with switching drugs. The HbA1c level 
was 6.8%±0.9% at baseline, 6.4%±0.4% at 12 weeks after 
switching, and 6.5%±0.5% at 24 weeks after switching in 
group 1 and 8.0%±1.4% at baseline, 8.2%±1.4% at 12 weeks 
after switching, and 8.0%±1.2% at 24 weeks after switching in 
group 2 (Fig. 1). The glycemic profiles and the baseline HbA1c, 
FPG, and 2h-PPG levels were better in group 1 than in group 2; 
however, other clinical parameters, including age, duration of 
diabetes, BMI, HOMA-IR, HOMA-β, and the doses of metfor-
min and glimepiride, did not differ between the two groups 
(Table 2). A multivariate logistic regression analysis was per-
formed to predict HbA1c levels of ≤7% at 12 weeks after the 
switch from glimepiride to sitagliptin to identify the best candi-
dates for the switch (Table 3). Age, sex, BMI, duration of dia-
betes, doses of glimepiride and metformin, baseline HbA1c, 
HOMA-IR, and HOMA-β were used as independent variables. 
After adjusting for other factors, a low baseline HbA1c level 
and high HOMA-IR were predictors of efficacy after switching 
from glimepiride to sitagliptin.
DISCUSSION
We analyzed 61 Korean patients with type 2 diabetes who 
switched from glimepiride to sitagliptin because of clinical hy-
poglycemia. We investigated the efficacy and safety of sita-
gliptin treatment and identified good candidates for the drug 
switch. The mean duration of diabetes was approximately 8 
years, and these patients were treated with glimepiride and 
metformin combination therapy. Glycemic control was accept-
able, indicated by a mean HbA1c level of approximately 7.5%; 
however, symptomatic hypoglycemia was evident. The switch 
did not aggravate glycemic control, and there was a trend to-
wards decreasing HbA1c levels, by 0.1% and 0.2% after 12 
and 24 weeks, respectively. The proportion of patients who 
Table 2. Comparison of Clinical and Laboratory Data accord-
ing to Glycemic Control 12 Weeks after Switching Drugs
Variable
Group 1  
(HbA1c ≤7%) 
(n=27)
Group 2 
(HbA1c >7%) 
(n=34)
P value
Age, yr 59±13 59±9 0.878
Male sex   10 (37)      15 (44.1) 0.384
BMI, kg/m2 25.1±2.8 24.4±3.4 0.331
Duration of diabetes, yr 7.9±9.4 9.6±7.9 0.467
Fasting plasma glucose, 
   mg/dL
119.9±30 145.4±36 0.004
Postprandial plasma 
   glucose, mg/dL
186.0±65.9 242.2±58.8 0.002
HbA1c, % 6.8±0.9 8.0±1.4 <0.001
Total cholesterol, mg/dL 170.4±40.4 178.1±35.5 0.442
HDL-C, mg/dL 47.3±14.4 48.9±12.6 0.654
LDL-C, mg/dL 90.9±36.9 100.1±27.9 0.288
Triglyceride, mg/dL 172.8±93.3 148.6±82.6 0.296
HOMA-IR 5.1±5.3 5.0±5.4 0.928
HOMA-β 41.1±30.8 48.2±31.4 0.506
Glimepiride dose, mg/day 2.3±1.4 2.7±1.9 0.323
Metformin dose, mg/day 946±451 1,033±498 0.476
Values are expressed as mean±SD or number (%).
HbA1c, glycated hemoglobin; BMI, body mass index; HDL-C, high 
density lipoprotein cholesterol; LDL-C, low density lipoprotein cho-
lesterol; HOMA-IR, homeostasis model assessment of insulin resis-
tance; HOMA-β, homeostasis model assessment of β-cell function. 
Table 3. Multivariate Logistic Regression Analysis for Pre-
dicting a HbA1c Level ≤7% 12 Weeks after Switching from 
Glimepiride to Sitagliptin
Variable OR (95% CI) P value
Age, yr 1.108 (0.913–1.343) 0.300
Gender, male 1.079 (0.015–79.913) 0.972
BMI, kg/m2 0.931 (0.515–1.684) 0.813
Duration of diabetes, yr 0.973 (0.665–1.424) 0.889
HbA1c, % 0.008 (0.000–0.643) 0.031
HOMA-IR 1.643 (1.067–2.529) 0.024
HOMA-β 0.988 (0.944–1.035) 0.622
Glimepiride dose, mg/day 1.598 (0.426–5.997) 0.487
Metformin dose, mg/day 1.000 (0.995–1.005) 0.993
HbA1c, glycated hemoglobin; BMI, body mass index; HOMA-IR, 
homeostasis model assessment of insulin resistance; HOMA-β, ho-
meostasis model assessment of β-cell function. 
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reached the target HbA1c level of <7% increased from 31.1% 
to 44.3% after switching drugs. While FPG did not change, 2h-
PPG and symptomatic hypoglycemia decreased significantly. 
These results suggest that patients with dominant insulin resis-
tance, particularly those with frequent hypoglycemia or a high 
risk for hypoglycemia, may benefit from switching drugs.
 Sulfonylureas exert their antihyperglycemic action by stimu-
lating pancreatic β-cells to produce insulin. These agents are a 
proven and potent therapy for patients with type 2 diabetes 
mellitus. However, hypoglycemia is a common side effect of 
these drugs. Hypoglycemia is related to poor clinical outcomes 
including increased risk for cardiovascular disease and overall 
mortality in patients with type 2 diabetes [11-13]. Furthermore, 
β-cell preservation is another critical problem, and treating pa-
tients with sulfonylureas often results in secondary failure. 
Secondary failure has two major causes: eventual exhaustion 
of β-cells caused by the sulfonylurea treatment itself and glu-
cose toxicity induced by poor glycemic control, resulting in re-
duced pancreatic β-cell responsiveness [14,15]. Sitagliptin, a 
DPP-4 inhibitor, has recently been used widely to increase in-
sulin secretion in a glucose-dependent manner, potentially pre-
senting a good choice for glucose control with a low risk of hy-
poglycemia. Several preclinical studies have shown that DPP-4 
inhibitors increase the number of pancreatic β-cells and im-
prove their function [7,16,17]. Shirakawa et al. [18] reported 
the protective effects of DPP-4 inhibitors against increased 
β-cell apoptosis induced by dietary sucrose and linoleic acid in 
a mouse model of diabetes mellitus. Several studies have com-
pared the efficacy of DPP-4 inhibitors and sulfonylureas. 
Arechavaleta et al. [19] showed that adding sitagliptin or 
glimepiride led to similar improvements in glycemic control in 
patients with type 2 diabetes on metformin monotherapy. An-
other study showed that the addition of sitagliptin, compared 
with glipizide, produced the same results [20]. Sitagliptin was 
generally well tolerated in both studies, with a lower risk of hy-
poglycemia and weight loss compared with the two sulfonyl-
ureas glimepiride and glipizide. The rate of severe hypoglyce-
mia was as high as 1.5% over 2 years with sulfonylurea use but 
was very rare with DPP-4 inhibitor use. Considering the results 
of those studies, DPP-4 inhibitors appear to be possible re-
placements for sulfonylureas due to their comparable efficacy 
and obvious superiority in terms of adverse effects and long-
term β-cell preservation.
 Many efforts have been made to evaluate the efficacy of 
DPP-4 inhibitors after combining them with another oral hypo-
glycemic agent, such as metformin, or using them as mono-
therapy. We evaluated the switch from a sulfonylurea to a DPP-
4 inhibitor in an actual clinical setting, particularly in patients 
with frequent hypoglycemia. Kim et al. [21] showed that 
switching from a low dose sulfonylurea (average dose of 1.8 
mg glimepiride and 30 mg gliclazide modified release) did not 
change the HbA1c or FPG levels. Chung and Lee [22] reported 
similar results in 45 patients who switched from glimepiride 
(average dose, 3.44 mg/day) to sitagliptin. In addition, they 
suggested considering a switch in relatively well-controlled pa-
tients with frequent hypoglycemia [22]. Our results show that 
the overall glycemic control was not aggravated. Furthermore, 
postprandial glycemic control improved in patients who 
switched from glimepiride to sitagliptin. Many studies have re-
ported postprandial hyperglycemia as a major cause of adverse 
cardiovascular disease in patients with diabetes mellitus [23]. 
In addition, variations in glucose contribute to the development 
and progression of atherosclerosis [24]. Thus, strategies to im-
prove postprandial hyperglycemia and reduce variations in glu-
cose are an important focus in diabetes management. In this 
study, 2h-PPG decreased by >20 mg/dL after the drug switch. 
We did not check the exact variations in glucose; however, it 
can be inferred that sitagliptin reduced glucose excursions in 
these patients according to the slightly increased FPG level and 
markedly decreased 2h-PPG level. Thus, this may be another 
benefit for postprandial glucose control after switching to a 
DPP4-inhibitor.
 We also identified good candidates for the switch from a 
sulfonylurea to sitagliptin. In previous clinical studies, high 
baseline HbA1c [25,26], low insulinogenic index [26], short 
duration of diabetes [21,26], and high BMI [27] were predic-
tors of sitagliptin efficacy. However, our study was different in 
that we did not use add-on therapy at the time of the sulfonyl-
urea-to-sitagliptin switch. In our study, patients with high 
HOMA-IR, an insulin sensitivity marker, achieved good gly-
cemic control after the switch to sitagliptin. DPP-4 inhibitors 
are well known to improve β-cell function [28,29]; however, 
improvements in insulin sensitivity remain controversial [25, 
30]. Hyperglycemia in patients with type 2 diabetes is caused 
by multiple defects, including insulin resistance, impaired in-
sulin secretion, and excessive hepatic glucose production. Sul-
fonylureas are representative oral hypoglycemia agents with-
out insulin sensitizing effects. However, incretin has pleiotro-
pic effects in addition to an insulin secretory effect [31]. A re-
cent rodent animal model study reported that sitagliptin mono-
therapy improved insulin sensitivity, as assessed by HOMA-
IR, and that this improvement was comparable to that using 
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metformin monotherapy [32]. Thus, if a patient has both insu-
lin resistance and a β-cell secretory defect, a sulfonylurea 
would improve insulin secretion only; however, sitagliptin 
may influence both defects, resulting in a greater reduction in 
HbA1c after drug switching. Our results suggest the clinical 
implications for this effect.
 This study had certain limitations. First, only a relatively 
small number of cases were included. Second, the definition of 
hypoglycemia was not accurate, and there was little documen-
tation on weight changes in patients before and after switching 
drugs. Third, we did not use a standardized meal when assess-
ing 2h-PPG levels, nor did we measure HOMA-IR or HOMA-β 
after switching drugs. Last, we could not compare the effects 
of drug switching with a control group because of the retro-
spective nature of the study. Despite these limitations, our re-
sults suggest that it is possible for patients with type 2 diabetes 
mellitus to switch from a low-dose sulfonylurea to a DPP-4 in-
hibitor, particularly those with a high risk for hypoglycemia 
while using a sulfonylurea. Of course, there is concern about 
the cost. Sulfonylureas offer an inexpensive and effective ther-
apy option for a worldwide pandemic. However, the switch to 
a safer DPP-4 inhibitor could be another choice to treat patients 
with a higher risk of hypoglycemia, including elderly, lean, or 
impaired renal function patients. DDP-4 inhibitors and GLP-1 
analogs have gained a significant market share in the USA [33].
 In conclusion, glycemic control was not aggravated, and 
2h-PPG improved 24 weeks after switching from glimepiride 
and metformin to sitagliptin and metformin. Approximately 
half of the patients achieved the goal of an HbA1c level ≤7% 
after the switch. Both documented and clinical hypoglycemia 
decreased remarkably after the drug switch. Patients with 
dominant insulin resistance could be good candidates for 
switching from a sulfonylurea to sitagliptin.
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